loader
Please Wait
Applying Filters...

Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Information, Expiry & Status of FDA Orange Book Patents covering 9006224

    Client Virtual Booth
    Menu

    Novartis Pharmaceuticals Corporation

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Bora Pharmaceuticals- Making success more certain.

    Send me more info on How To Grow My Business Digitally?

    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 NOVARTIS (4)

    filter

    01 9006224 (4)

    filter

    01 Blank (4)

    filter

    01 Blank (4)

    filter

    01 2028-07-01 (4)

    refreshReset Filter
    refreshReset Filter
    price-trendAsk Us

    NOVARTIS

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EVEROLIMUS

    PDF Supplier PDF
    URL Supplier Web Content
    9006224
    2028-07-01
    U-1681
    22334
    TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
    4
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    NOVARTIS

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EVEROLIMUS

    PDF Supplier PDF
    URL Supplier Web Content
    9006224
    2028-07-01
    U-1681
    22334
    TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
    1
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    NOVARTIS

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EVEROLIMUS

    PDF Supplier PDF
    URL Supplier Web Content
    9006224
    2028-07-01
    U-1681
    22334
    TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
    2
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    NOVARTIS

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    EVEROLIMUS

    PDF Supplier PDF
    URL Supplier Web Content
    9006224
    2028-07-01
    U-1681
    22334
    TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
    3
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Post Enquiry
    POST ENQUIRY